Is Cue Biopharma (CUE) overvalued? · rev $9.3M
Cue Biopharma (CUE) is a biotechnology company listed on US.
This page asks whether Cue Biopharma (CUE) looks expensive on cached numbers — not a short thesis.
Latest reported CUE revenue for 2024-12-31 was $9.3M. Net income was -$40.7M. Revenue was up 69.2% from 2023-12-31 to 2024-12-31. CUE currently screens at market cap $59.5M.
CUE currently screens at market cap $59.5M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next CUE 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the CUE stock page for the full model, not this heading.
Not investment advice.